Novo's Approach to Recruitment & Retention in CVOTs

About this session

How do you sustain engagement through multi-year outcome trials as a leading molecule expands into new therapy areas? Novo Nordisk found the answer as semaglutide expanded into other therapy areas: a purpose-built, cross-functional participant engagement model supported by continuous scientific and operational feedback loops, localised engagement tools, and transparent communication. The result was sustained community building, strengthening trust, and maintaining engagement and retention across SELECT, FLOW, and SOUL globally.

Speakers

• AD

  Adam Dubayev

  Senior Global Manager · Novo Nordisk

  Speaker

• EH

  Elin Hilstrøm Hoffmann

  Clinical Project Lead · Novo

  Speaker